An advertisement or flyer for FDA REMS-Compliant continuing education programs for opioid analgesics. The main text of the image is "Opioid misuse and abuse on the rise: Help address this serious public health concern." It has a blue background with white text. On the left side of the image there is a photo of a woman with curly hair and glasses wearing a white lab coat and a stethoscope around her neck. She is looking off to the side with a thoughtful expression on her face.
The text on the image also reads "100 million adults suffer from chronic pain. There are many FDA REMS-Compliant CE Programs for opioid analgesics available dedicated to: Improving safety and appropriate prescribing. Maintaining patient access to medication. Reducing serious adverse outcomes. Take a CE Program today. Visit www.opioidce.com."
At the bottom of the infographic there is a citation as well as a disclaimer. It reads: "These educational activities are supported by an independent educational grant from the REMS Program Companies. Please visit www.xxx.com for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesics REMS education requirements issued by the US Food & Drug Administration."
Description 
Type
Category
-
Date
2016
Collection
We encourage you to view the image in the context of its source document(s) and cite the source(s) when using these images. However, to cite just this image alone, click the “Cite This Image” button and then paste the copied text.
![A screenshot from the Exalgo website. It appears to show case studies for how to convert different example patients to Exalgo step-by-step. The website is of example patient Dennis and the "Dose Conversion" step is selected. The website has a blue and white color scheme with a blue header and black footer.<br /><br />The main text of the page reads "Exalgo could give Dennis the pain relief he wants - with a once-daily dose. Double-blind placebo-controlled withdrawal study of opioid-tolerant patients with low back pain (447 enrolled 268 randomized; 66[49%] EXALGO patients and 44 [31%) placebo patients completed the study". Below that there is additional text that reads "Conversion/Titration Phase: EXALGO reduced mean pain intensity (NRS*) by 50% in successfully converted patients". <br /><br />The bottom of the page also has indication and important risk information. In the lower right corner there is an image of a person walking a dog on a leash with a tree in the background. The footer has the Exalgo logo and a navigation menu.](https://oida-resources-images.azureedge.net/public/full/788d6c94-1a49-4186-9b61-4e458d11f420.png)
